Trial Profile
Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naive HIV-1 Infected Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 20 Sep 2018 Status changed from recruiting to completed.
- 08 Nov 2012 Planned End Date changed from 1 Sep 2012 to 1 Sep 2014 according to ClinicalTrials.gov record.
- 25 Sep 2010 New trial record